Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mechanisms underlying the oncogenic and tumour suppressor functions of IER3 [ChIP-seq]

ABSTRACT: Mechanisms underlying the oncogenic and tumour suppressor functions of IER3 [ChIP-seq]

PROVIDER: PRJNA1170326 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR30920039_1.fastq.gz	Fastqsanger.gz
	SRR30920039_2.fastq.gz	Fastqsanger.gz
	SRR30920040_1.fastq.gz	Fastqsanger.gz
	SRR30920040_2.fastq.gz	Fastqsanger.gz
	SRR30920041_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Mechanisms underlying the oncogenic and tumour suppressor functions of IER3 [RNA-seq]

Project description:Mechanisms underlying the oncogenic and tumour suppressor functions of IER3 [RNA-seq]

| PRJNA1170327 | ENA

Mechanisms underlying the oncogenic and tumour suppressor functions of IER3 [RNA-seq]

Project description:The IER3 (Immediate Early Response 3) gene exhibits a multifaceted role in cancer biology, acting as both a tumor suppressor and an oncogene depending on the specific cancer type. This duality underscores the complexity of molecular pathways. Despite its significance, there is a dearth of studies dedicated to elucidating the exact mechanisms underlying IER3's involvement in cancer development. Recently, we identified that IER3 functions as an oncogene in cervix, breast, and lung cancer cell lines. In this study, we demonstrate for the first time that IER3 acts as a tumor suppressor in Neuroblastoma.

2025-03-13 | GSE279085 | GEO

Mechanisms underlying the oncogenic and tumour suppressor functions of IER3 [ChIP-seq]

2025-03-13 | GSE279084 | GEO

LMTK3 Represses Tumour Suppressor-Like Genes through Chromatin Remodeling in Breast Cancer

Project description:LMTK3 is an oncogenic receptor tyrosine kinase (RTK) implicated in various types of cancer including breast, lung, gastric and colorectal. It is localized in different cellular compartments but its nuclear function has not been investigated thus far. We have mapped LMTK3 binding across the genome using ChIP-seq and found that LMTK3 binding events are correlated with repressive chromatin markers. We further identified KRAB associated protein-1 (KAP1) as a novel binding partner of LMTK3. The LMTK3/KAP1 interaction is stabilized by PP1_, which suppresses KAP1 phosphorylation specifically at LMTK3-associated chromatin regions, inducing chromatin condensation and resulting in transcriptional repression of LMTK3-bound tumour suppressor-like genes. Furthermore, LMTK3 functions at enhancer regions in tethering the chromatin to the nuclear periphery, resulting in H3K9me3 modification and gene silencing. In summary, we propose a new model where a scaffolding function of nuclear LMTK3 promotes cancer progression through chromatin remodeling, revealing a new mechanism of RTK activity. Examination of LMTK3 binding profile in 2 cell types.

2015-06-30 | E-GEOD-70385 | biostudies-arrayexpress

Cyclin C is a haploinsufficient tumour suppressor

Project description:Cyclin C was cloned as a growth-promoting G1 cyclin, and was also shown to regulate gene transcription. Here we report that in vivo cyclin C acts as a haploinsufficient tumour suppressor, by controlling Notch1 oncogene levels. Cyclin C activates an 'orphan' CDK19 kinase, as well as CDK8 and CDK3. These cyclin-C-CDK complexes phosphorylate the Notch1 intracellular domain (ICN1) and promote ICN1 degradation. Genetic ablation of cyclin C blocks ICN1 phosphorylation in vivo, thereby elevating ICN1 levels in cyclin-C-knockout mice. Cyclin C ablation or heterozygosity collaborates with other oncogenic lesions and accelerates development of T-cell acute lymphoblastic leukaemia (T-ALL). Furthermore, the cyclin C encoding gene CCNC is heterozygously deleted in a significant fraction of human T-ALLs, and these tumours express reduced cyclin C levels. We also describe point mutations in human T-ALL that render cyclin-C-CDK unable to phosphorylate ICN1. Hence, tumour cells may develop different strategies to evade inhibition by cyclin C.

2014-09-02 | GSE58712 | GEO

LMTK3 Represses Tumour Suppressor-Like Genes through Chromatin Remodeling in Breast Cancer

Project description:LMTK3 is an oncogenic receptor tyrosine kinase (RTK) implicated in various types of cancer including breast, lung, gastric and colorectal. It is localized in different cellular compartments but its nuclear function has not been investigated thus far. We have mapped LMTK3 binding across the genome using ChIP-seq and found that LMTK3 binding events are correlated with repressive chromatin markers. We further identified KRAB associated protein-1 (KAP1) as a binding partner of LMTK3. The LMTK3/KAP1 interaction is stabilized by PP1α, which suppresses KAP1 phosphorylation specifically at LMTK3-associated chromatin regions, inducing chromatin condensation and resulting in transcriptional repression of LMTK3-bound tumour suppressor-like genes. Furthermore, LMTK3 functions at enhancer regions in tethering the chromatin to the nuclear periphery, resulting in H3K9me3 modification and gene silencing. In summary, we propose a model where a scaffolding function of nuclear LMTK3 promotes cancer progression through chromatin remodeling, revealing a previously undescribed mechanism of RTK activity.

2019-10-30 | PXD002399 | Pride

Clariom S human microarray HCT116 tumour suppressor overexpression

Project description:overexpression of tumour suppressor ZAR1 in HCT116 (HCT116 wt and HCT116 delp53) colon carcinoma cell line (EYFPemtpy and ZAR1EYFP), sorted by Aria for fluorescent cells, RNA isolation

2020-08-27 | E-MTAB-8292 | biostudies-arrayexpress

CBX7 is a tumour suppressor that inhibits bladder cancer

Project description:CBX7 is a tumour suppressor that inhibits bladder cancer

| PRJNA664510 | ENA

LMTK3 Represses Tumour Suppressor-Like Genes through Chromatin Remodeling in Breast Cancer

2015-06-30 | GSE70385 | GEO

Mapping in silico genetic networks of tumour suppressor gene to uncover novel functional associations and cancer cell vulnerabilities

Project description:Cancers harbouring loss-of-function (LOF) alterations in tumour suppressor genes lack targeted therapies, thus alternative means to characterise gene function and identify vulnerabilities in these cancer cells are required. Here, we map the in silico genetic networks of KMT2D, a frequently mutated tumour suppressor gene, to demonstrate its utility in uncovering novel functional associations and vulnerabilities in cancer cells with tumour suppressor gene LOF alterations. In silico KMT2D networks revealed associated with histone modification, DNA replication, metabolism, and immune response. We identified synthetic lethal (SL) candidates encoding exising therapeutic targets. Analysing patient data from The Cancer Genome Atlas (TCGA) and the Personalized OncoGenomics Project (NCT021556210), we showed dysregulated pathways associated with SL candidates and elevated immune checkpoint response markers in KMT2DLOF cases, bringing forth evidence supporting KMT2D as a biomarker for immune checkpoint inhibitors. Our study presents a framework for identifying targetable vulnerabilities in cancers with tumour suppressor gene alterations.

2024-10-18 | PXD048272 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data